Skip to main content
SpringerLink
Log in
Book cover

Cancer du sein pp 369–376Cite as

Peut-on se passer des anthracyclines?

  • Conference paper

  • 269 Accesses

Abstrait

La question peut paraître saugrenue, les anthracyclines sont reconnues comme une classe thérapeutique majeure dans le traitement chimiothérapique des cancers du sein, au même titre que les taxanes. La quasi-totalité des études récentes — en fait toutes sauf deux à notre connaissance — a utilisé des anthracyclines dans l’évaluation des protocoles comportant des taxanes; ces études peuvent-elles, à elles seules, inverser la tendance qui considère que l’indication des anthracyclines en adjuvant est « gravée dans le marbre »?

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Bonneterre J, Roché H, Kerbrat P et al. (2005) Epirubicin increases long term survival in adjuvant chemotherapy of patients with poor prognosis, node positive, early breast canceer: 10-year follow up results of the French Adjuvant Study Group 05 randomised trial. J Clin Oncol 23: 2686–2693

    Article  PubMed  CAS  Google Scholar 

  2. Bonneterre J, Roché H, Kerbrat P et al. (2004) Long term cardiac follow-up in relapse free patients after six courses of fluorouracil, epirubicin and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group. J Clin Oncol 22: 3070–3079

    Article  PubMed  CAS  Google Scholar 

  3. Burnell M, Levine M, Chapman JA et al. (2006) A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC-CTG MA21: results of an interim analysis; Breast Cancer Res Treat (Suppl 1): abstract 53

    Google Scholar 

  4. Buzdar AU, Ibrahim NK, Francis D et al. (2005) Significantly higher pathological complete response rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor 2-positive operable breast cancer. J Clin Oncol 23: 3676–3685

    Article  PubMed  CAS  Google Scholar 

  5. Campone M, Roche H, Kerbrat P et al. (2005) Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann Oncol 16: 1343–1351

    Article  PubMed  CAS  Google Scholar 

  6. Chia S, Clemons M, Martin LA et al. (2006) Pegylated liposomal doxorubicin and trastuzumab in HER2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 24: 2773–2778

    Article  PubMed  CAS  Google Scholar 

  7. Di Leo A, Larsimont D, Gancberg D et al. (2001) HER2 and topoisomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12: 1081–1089

    Article  Google Scholar 

  8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 365: 1687–1717

    Article  CAS  Google Scholar 

  9. Fumoleau P, Roché H, Kerbrat P et al. (2002) Cardiac toxicity in operable breast cancer patientsafter adjuvant chemotherapy with epirubicin; 7 year analysis in 3577 patients of the French Adjuvant Study Group trials. Breast cancer Res Treat 76(Suppl 1) 5157, abstract 640

    Google Scholar 

  10. Henderson IC, Berry DA, Demetri GD et al. (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol 21: 976–983

    Article  PubMed  CAS  Google Scholar 

  11. Jones SE, Savin MA, Holmes FA et al. (2006) PhaseIII trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24: 5381–5387

    Article  PubMed  CAS  Google Scholar 

  12. Knoop AS, Knudsen H, Balslev E et al. (2006) Retrospective analysis oftopoisomerasella amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned tocyclophosphamide, methotrexate andfluorouracil or cyclophosphamide, epirubicin and fluorouracil/ Danish Breast cancer Cooperative Group. J Clin Oncol 24: 7483–7490

    Google Scholar 

  13. Levine MN, Pritchard KI, Bramwell VHC et al. (2005) Randomised trial comparing cyclophosphamide, epirubicin and fluoraouracil with cyclophosphamide methotrexate and fluorouracil in premenopausal women with breast cancer: update ofNational Cancer Institute of Canada Clinical Trials, Group Trial M5. J Clin Oncol 22: 5166–5170

    Article  CAS  Google Scholar 

  14. Martin M, Pienkowski T, Mackey J et al. (2005) Adjuvant docetaxel for Node-positive breast cancer. N Engl J Med 352: 2302–2313

    Article  PubMed  CAS  Google Scholar 

  15. Ng A, Taylor GM, Eden OB (2000) Treatment related leukaemia-a clinical and scientific challenge. Cancer Treat Rev 26: 377–391

    Article  PubMed  CAS  Google Scholar 

  16. Pegram MD, Konecny GE, O’Callaghan C et al. (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer; J Natl cancer Inst 96: 739–749

    Article  PubMed  CAS  Google Scholar 

  17. Perez EA, Suman VJ, Davidson NE et al. (2004) Effect of Doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N 9831 Intergroup Adjuvant Trial. J Clin Oncol 22: 3700–3704

    Article  PubMed  CAS  Google Scholar 

  18. Piccart MJ, Di Leo A, Beauduin M et al. (2001) Phase III Trial comparing wo dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in Node-positive breast cancer. J Clin Oncol 19: 3103–3110

    PubMed  CAS  Google Scholar 

  19. Poole CJ, Earl HM, Hiller L et al. (2006) Epirubicin and cyclophosphamide, methotrexate, and fluorouraccil as adjuvant therapy for early breast cancer. N Engl J Med 355: 1851–1862

    Article  PubMed  CAS  Google Scholar 

  20. Praga C, Bergh J, Bliss J et al. (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23: 4179–4191

    Article  PubMed  CAS  Google Scholar 

  21. Pritchard Kl, Sheperd LE, O’Malley F et al. (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354: 2103–2111

    Article  PubMed  CAS  Google Scholar 

  22. Roché H, Fumoleau P, Spielmann P et al. (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS01 trial. J Clin Oncol 36: 5664–5671

    Article  CAS  Google Scholar 

  23. Slamon D, Eiermann W, Robert N et al. (2005) Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim efficacy analysis; Breast Canc Res Treat 94(Suppl 1): S5, Abstract 1

    Google Scholar 

  24. Slamon D, Eiermann W, Robert N et al. (2006) BCIRG 006: 2nd interim analysis of a phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (Ac-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with doxorubicin, carboplatine and trastuzumab (TCH) in HER2 positive early breast cancer patients. Breast Cancer Res Treat 100(Suppl 1): abstract 52

    Google Scholar 

  25. Smith RE, Bryant J, De Cillis A et al. (2003) Acute myeloid leukemia and myelodysplastic syndrome after doxorubicinecyclophosphamide adjuvant therapy for operable breast cancer: the NSABP experience. J Clin Oncol 21: 1195–1204

    Article  PubMed  CAS  Google Scholar 

  26. Tan-Chiu E, Yothers G, Romond E et al. (2005) Assessment of cardiac dysfunction in a randomised trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23: 7811–7819

    Article  PubMed  CAS  Google Scholar 

  27. Tanner M, Isola J, Wiklund T et al. (2006) Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose escalated anthracycline-based adjuvant chemotherapy in HER2/neu amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24: 2428–2436

    Article  PubMed  CAS  Google Scholar 

  28. Untch M, Eidtmann H, du Bois A et al. (2004) Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 40: 988–997

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de cancérologie-gynécologie, Centre Oscar-Lambret, Rue Frédéric-Combernale, 59020, Lille cedex

    J. Bonneterre

Authors
  1. J. Bonneterre
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France, Paris

About this paper

Cite this paper

Bonneterre, J. (2007). Peut-on se passer des anthracyclines?. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-287-71478-8_35

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-71478-8_35

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-71477-1

  • Online ISBN: 978-2-287-71478-8

Publish with us

Policies and ethics

Search

Navigation